Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

XTLB

X.T.L. Biopharmaceuticals Ltd. ADR

Last Close
Jun 14 • 04:00PM ET
2.04
Dollar change
-0.13
Percentage change
-6.21 		%
Scroll to Statements
Index- P/E- EPS (ttm)-0.07 Insider Own2.46% Shs Outstand5.45M Perf Week-10.13%
Market Cap11.12M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.31M Perf Month-25.55%
Income-0.38M PEG- EPS next Q- Inst Own4.75% Short Float0.41% Perf Quarter131.82%
Sales0.00M P/S- EPS this Y- Inst Trans-0.81% Short Ratio0.03 Perf Half Y98.06%
Book/sh0.50 P/B4.11 EPS next Y- ROA-12.10% Short Interest0.02M Perf Year65.37%
Cash/sh0.43 P/C4.75 EPS next 5Y- ROE-13.07% 52W Range0.75 - 4.99 Perf YTD101.96%
Dividend Est.- P/FCF- EPS past 5Y- ROI-13.97% 52W High-59.12% Beta1.20
Dividend TTM- Quick Ratio11.43 Sales past 5Y0.00% Gross Margin- 52W Low172.00% ATR (14)0.22
Dividend Ex-Date- Current Ratio11.43 EPS Y/Y TTM86.44% Oper. Margin0.00% RSI (14)34.24 Volatility10.33% 9.35%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q152.66% Payout- Rel Volume0.01 Prev Close2.17
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume745.69K Price2.04
SMA20-18.19% SMA50-21.14% SMA20042.12% Trades Volume9,271 Change-6.21%
Date Action Analyst Rating Change Price Target Change
May-08-15Initiated H.C. Wainwright Buy $6
Jun-05-24 09:15AM
XTL Entered Definitive Agreement to Acquire The Social Proxy
(GlobeNewswire)
May-13-24 07:23AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
(InvestorPlace) +14.06%
Apr-29-24 07:33AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
(InvestorPlace)
Mar-20-24 10:15AM
XTL To Aquire The Social Proxy
(GlobeNewswire) +128.85%
Oct-20-23 04:00PM
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
(GlobeNewswire)
04:00PM Loading…
04:00PM
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
(GlobeNewswire)
Nov-21-18 08:00AM
Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications
(GlobeNewswire)
Nov-01-18 10:09AM
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
(PR Newswire) -10.32%
Jul-24-18 09:09AM
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update
(PR Newswire)
May-29-18 05:37PM
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update
(PR Newswire)
Dec-13-17 07:30AM
Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells
(ACCESSWIRE)
Dec-06-17 12:08PM
XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
(PR Newswire)
Nov-27-17 10:30AM
XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results
(PR Newswire)
Oct-23-17 11:23AM
XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements
(PR Newswire) +5.53%
Oct-06-17 07:30AM
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy
(ACCESSWIRE)
07:50AM Loading…
Oct-05-17 07:50AM
Earnings Review and Free Research Report: DelMar Missed Earnings Expectations
(ACCESSWIRE)
Sep-26-17 09:23AM
XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update
(PR Newswire)
Sep-12-17 09:00AM
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
(PR Newswire)
Jul-11-17 07:00AM
Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update
(Accesswire)
Jun-15-17 09:00AM
XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update
(PR Newswire)
Apr-27-17 09:50AM
XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors
(PR Newswire)
Apr-05-17 09:10AM
XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome
(PR Newswire)
Mar-30-17 08:55AM
XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update
(PR Newswire) +6.30%
Mar-22-17 09:22AM
XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors
(PR Newswire)
Mar-07-17 12:40PM
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors
(PR Newswire) +6.97%
Mar-01-17 08:30AM
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement
(PR Newswire)
Feb-17-17 08:00AM
XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering
(PR Newswire) -34.92%
Feb-13-17 09:08AM
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
(PR Newswire) -8.23%
Jan-25-17 08:30AM
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
(PR Newswire)
Jan-05-17 08:30AM
XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome
(PR Newswire) +11.86%
08:00AM Loading…
Dec-19-16 08:00AM
XTL Biopharmaceuticals to Present at Biotech Showcase
(PR Newswire) -19.07%
Dec-06-16 08:30AM
XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update
(PR Newswire)
Nov-09-16 01:25PM
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements
(PR Newswire) -6.60%
Sep-27-16 08:30AM
XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update
(PR Newswire)
Sep-07-16 08:32AM
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1
(PR Newswire) +10.99%
Sep-06-16 08:00AM
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
(PR Newswire) -9.00%
Aug-11-16 09:00AM
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1
(PR Newswire)
Jun-02-16 09:11AM
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected 4 Billion Dollar Market
Jun-01-16 08:30AM
XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update
(PR Newswire) +6.79%
May-16-16 11:45AM
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016
(PR Newswire)
Apr-07-16 01:04PM
XTL BIOPHARMACEUTICALS LTD Financials
Mar-31-16 09:45AM
XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update
(PR Newswire) -6.22%
Mar-21-16 08:30AM
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus
(PR Newswire)
Mar-09-16 08:29AM
Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals
(PR Newswire)
Mar-02-16 09:00AM
XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent in Hungary for Lupus Drug hCDR1
(PR Newswire)
Feb-22-16 09:02AM
XTL Biopharmaceuticals Receives European Medicines Agency's SME Status
(PR Newswire) +5.83%
Feb-10-16 08:30AM
XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
(PR Newswire)
Jan-27-16 08:30AM
XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America
(PR Newswire)
Jan-25-16 08:30AM
XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1
(PR Newswire)
Jan-13-16 08:30AM
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
(PR Newswire)
Jan-11-16 08:30AM
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
(PR Newswire) -8.39%
Dec-01-15 08:30AM
XTL Biopharmaceuticals Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016
(PR Newswire) +7.74%
Nov-09-15 08:30AM
Cellect Biomed Announces Key Leadership Changes
(GlobeNewswire)
Oct-28-15 09:00AM
Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a Phase II Clinical Study of hCDR1 (Edratide) for the Treatment of Lupus
(PR Newswire)
Oct-26-15 09:15AM
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
(PR Newswire) +13.66%
Oct-13-15 08:45AM
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
(PR Newswire)
Sep-17-15 11:40AM
XTL Biopharmaceuticals Ltd. Earnings Q2, 2015
Sep-03-15 09:00AM
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
(PR Newswire) +8.82%
Sep-01-15 09:00AM
XTL Biopharmaceuticals Reports Second Quarter 2015 Results
(PR Newswire)
Aug-26-15 09:00AM
XTL Announces Publication of Results of Phase 2 Study on hCDR1 (Edratide) in Patients with Active Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine
(PR Newswire)
Jun-01-15 08:00AM
XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets
(PR Newswire)
May-11-15 10:50AM
XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference
(PR Newswire)
May-09-15 09:45AM
4 Speculative Biotechs With Huge Analyst Targets
(24/7 Wall St.)
May-08-15 09:35AM
XTL Biopharmaceuticals Aims To Tame Lupus, HC Wainwright Initiates At Buy
+11.66%
07:43AM
Coverage initiated on XTL Biopharma by H.C. Wainwright
Apr-28-15 07:45AM
XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014
(PR Newswire)
Mar-31-15 09:30AM
XTL Biopharmaceuticals Announces Pricing of $4.0 Million Registered Direct Offering
(PR Newswire)
Feb-17-15 08:30AM
Biotech Investor Alex Rabinovich Increases Stake in XTL Biopharmaceuticals
(PR Newswire)
Dec-30-14 12:23PM
XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors
(PR Newswire)
Dec-08-14 08:30AM
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
(PR Newswire) -6.72%
Dec-01-14 08:00AM
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014
(PR Newswire)
Sep-02-14 12:09PM
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
(PR Newswire) -6.49%
Jul-22-14 02:54PM
XTL Hopes To Begin Major Lupus Trial Next Year
(Seeking Alpha)
Jul-16-14 09:18AM
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
(PR Newswire)
Jun-12-14 08:00AM
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
(PR Newswire) +20.19%
Jun-02-14 09:00AM
XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014
(PR Newswire)
May-19-14 08:00AM
XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts
(PR Newswire)
Apr-02-14 04:41PM
XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013
(PR Newswire) +22.22%
Mar-25-14 08:00AM
XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial
(PR Newswire)
Jan-08-14 08:00AM
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus
(PR Newswire) +15.38%
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.